Practices should be evaluated for cytotoxic chemotherapy extravasation
the ONA take:
The influence of patient experience in health care is driving a review of practices to ensure it plays a part in developing clinical practice guidelines.
This literature review sought to analyze the quality of evidence that supports management practices of cytotoxic drug extravasation and determine if the patient experience is taken into account.
A literature search identified all studies on strategies aimed at preventing surgical debridement and all studies evaluating the patient’s perspective on extravasation management published from the 1960s to July 2014.
The researchers found no conclusive evidence that one clinical strategy is more effective than another, and no studies evaluated management strategies from the patient perspective.
The researchers suggest further outcomes-based studies are needed for extravasation management guidelines and how treatment impacts the patient.
In addition, they conclude that research into the patient experience of extravasation management needs to be addressed.
This literature review sought to analyze the quality of evidence that supports management practices of cytotoxic drug extravasation.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|